Synta Pharmaceuticals Corp. (SNTA)

zzlangerhans (99.57) Submitted: 11/7/2009 9:19:42 PM : Start Price: $3.15 SNTA Score: -21.00

Synta crawls back over 100M yet again despite their inability to come to terms with the failure of elesclomol. HSP-90 and preclinical programs do not justify 50M above shareholder equity.

TSIF (98.76) Submitted: 11/5/2009 1:28:21 PM : Start Price: $2.98 SNTA Score: -27.09

Bios have bitten me lately, both my up and down calls, but I guess there is no cure for my playing them. I've played Synta before and I see little change in the fundamentals. Synta posted a profit today...great for a baby pharm!!! But where did it come from when it has $4 Million per quarter of revenue and $10-22 Million quarterly of R&D and other expenses and no drug on FDA approval list? An accelerated payment from a partnership with GlaxoSmithKline that was cancelled after halting drug testing of it's metastatic melanoma drug, elesclomos, in late stage testing last February. Drug is cancelled, subtract out the payment and we have the same quarterly loss as always. The only good news is more cash in the coffers to continue development of other drugs, but half of their R&D team was cut after the failure of elesclomos to treat metastatic melanoma. Other drugs are still in pre-clinical, two years plus or more away (with the huge assumption that it's approvable, effective, safe, etc), and no signed partners. Deals limit cash exposure. Cash is good until about 2012, but there is no catalyst on the horizon to warrant the boost in Synta's share price after receiving an advance of their milestone payments from GSK on a failed product.

ssbb123 (72.12) Submitted: 9/24/2009 10:29:35 AM : Start Price: $2.96 SNTA Score: -26.58

From the Annual 10Q filed on 8/4/09
"We have devoted substantially all of our capital resources to the research and development of our drug candidates. Since our inception, we
have had no revenues from product sales. We have never been profitable and, as of June 30, 2009, we had an accumulated deficit of
$424.7 million. We expect to incur significant operating losses for the foreseeable future as we advance our drug candidates from discovery
through preclinical development and clinical trials, and seek regulatory approval and eventual commercialization. We will need to generate
significant revenues to achieve profitability and may never do so."

Founded in 2000, never been profitable, may never be, That's enough for me, red thumb

TuffPicks (59.92) Submitted: 9/22/2009 12:17:50 PM : Start Price: $3.15 SNTA Score: +21.03

wallstreet buy list

OklaBoston (< 20) Submitted: 9/18/2009 1:19:13 AM : Start Price: $3.13 SNTA Score: +21.70

Positive earnings surprise last quarter plus the CEO's recent purchase of shares on the open market. That's not a typo, the CEO!

ChicagoBreeze (< 20) Submitted: 10/23/2008 3:41:04 PM : Start Price: $5.72 SNTA Score: -56.75

Promising risky microcap biotech for various types of cancer with phase 3 interium results later out this year. One person described this as possiblly the "next celgene". Also has high insider ownership. NO insiders have sold since it went public nearly 2 years ago.

biovestor (< 20) Submitted: 6/28/2008 6:22:16 AM : Start Price: $5.93 SNTA Score: -22.95

A cancer biotech stock with a promising Phase 3 candidate for metastatic melanoma (elesclomol) along with a full early stage pipeline.

glfraley (97.36) Submitted: 1/29/2008 3:14:44 PM : Start Price: $7.15 SNTA Score: -29.59

Just won orphan status for their already fast tracked melanoma drug. should be interesting to see how this develops.

ivhadit (< 20) Submitted: 1/19/2008 6:41:50 PM : Start Price: $6.50 SNTA Score: -30.07

IF THIS HITS WATCH OUT

Dtrifan (68.97) Submitted: 11/13/2007 9:49:01 PM : Start Price: $8.37 SNTA Score: -30.57

Cancer drug market at a low price

jcarcopo (21.06) Submitted: 10/19/2007 9:55:47 AM : Start Price: $8.11 SNTA Score: -27.31

Promising Melanoma (#1 Cancer Killer) Cancer Drug. $80M upfront from Glaxo, up to $1 Billion total for milestones. Fast R&D pipeline with several other drug canidates. Plenty of insider action at $9-$10. Stage 2 trial went well, stage 3 proceeding, FDA fast track drug candidate. $12-$14 easy within a month.

myersfield (< 20) Submitted: 10/11/2007 4:05:37 PM : Start Price: $9.01 SNTA Score: -30.78

Very promising data, 400% survival benefit in mal. melanoma w/o prior chemo as in current phase 3 trial.

tharlow (< 20) Submitted: 10/11/2007 12:12:31 AM : Start Price: $9.75 SNTA Score: -33.36

Ready to explode on GSK deal. An easy double from these discounted levels.

caslonsvcs (88.50) Submitted: 9/7/2007 2:00:30 PM : Start Price: $6.42 SNTA Score: -18.50

Skin cancer treatment that did very well in trials; coming to market in about 2 years.

agard43 (< 20) Submitted: 7/2/2007 12:20:09 AM : Start Price: $8.36 SNTA Score: -30.04

Highest Rated Russell 2000 stock and Insider Buying = Buy